RECRUITING
I'm interested ...!!
Immune Spatial Features of Guselkumab Cutaneous Response
This study examines the effect of IL-23 blockade with Guselkumab on the immune cells of scalp psoriasis lesions.
Conditions:
🦠 Psoriasis of Scalp
🗓️ Study Start (Actual) 1 July 2023
🗓️ Primary Completion (Estimated) 30 June 2026
✅ Study Completion (Estimated) 30 June 2026
👥 Enrollment (Estimated) 10
🔬 Study Type INTERVENTIONAL
📊 Phase PHASE4
Locations:
📍 San Francisco, California, United States

📋 Eligibility Criteria

Description

    Inclusion Criteria:

      Exclusion Criteria:

      • 1. taking systemic immunosuppressives in the last 4 weeks
      • 2. pregnancy
      • 3. severe immunodeficiency (either from genetic or infectious causes).
      • 4. tuberculosis or other active serious infection
      • 5. active systemic malignancy.
      • 6. breast-feeding
      • 7. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
      • 8. Males who are trying to conceive
      • -
    Ages Eligible for Study: 18 Years to N/A (ADULT, OLDER_ADULT)
    Sexes Eligible for Study: ALL
    Accepts Healthy Volunteers: Yes

    🗓️ Study Record Dates

    These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

    Study Registration Dates

    • First Submitted 4 May 2023
    • First Submitted that Met QC Criteria 4 May 2023
    • First Posted 15 May 2023

    Study Record Updates

    • Last Update Submitted that Met QC Criteria 25 August 2023
    • Last Update Posted 28 August 2023
    • Last Verified August 2023
    I'm interested ...!!